Evidence map›Paper›PMID 34501296›Full record

ArticleJournal of clinical medicine2021

Analysis of Clinicopathological Factors Influencing Survival in Patients with Renal Cell Carcinoma and Venous Tumor Thrombus.

Łukasz Zapała, Sumit Sharma, Michał Kunc, Piotr Zapała, Jakub Kłącz, Piotr Korczyński, Michał Lipowski, Michał Późniak, Tomasz Suchojad, Tomasz Drewa and 2 more

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Łukasz ZapałaClinic of General, Oncological and Functional Urology, Medical University of Warsaw, 02-005 Warsaw, Poland.ORCID 0000-0001-7340-280X
Sumit SharmaClinic of General, Oncological and Functional Urology, Medical University of Warsaw, 02-005 Warsaw, Poland.
Michał KuncDepartment of Pathomorphology, Medical University of Gdańsk, 80-214 Gdańsk, Poland.ORCID 0000-0001-9529-2381
Piotr ZapałaClinic of General, Oncological and Functional Urology, Medical University of Warsaw, 02-005 Warsaw, Poland.
Jakub KłączDepartment of Urology, Faculty of Medicine, Medical University of Gdańsk, 80-402 Gdańsk, Poland.ORCID 0000-0001-5010-9336
Piotr KorczyńskiDepartment of Urology, Regional Specialist Hospital, 26-060 Czerwona Góra, Poland.
Michał LipowskiDepartment of Urology, St. Lukas Specialist Hospital, 26-200 Końskie, Poland.
Michał PóźniakClinic of Urology, Dr Jurasz University Hospital, 85-094 Bydgoszcz, Poland.
Tomasz SuchojadDepartment of Urology, Regional Specialist Hospital, 26-060 Czerwona Góra, Poland.
Tomasz DrewaClinic of Urology, Dr Jurasz University Hospital, 85-094 Bydgoszcz, Poland.
Marcin MatuszewskiDepartment of Urology, Faculty of Medicine, Medical University of Gdańsk, 80-402 Gdańsk, Poland.
Piotr RadziszewskiClinic of General, Oncological and Functional Urology, Medical University of Warsaw, 02-005 Warsaw, Poland.

Funding

Warszawski Uniwersytet Medyczny Publication subsidy fund
6 · The paper itself

Abstract

This study aimed to define patients with renal cell cancer and coexisting tumor thrombus in order to address concerns regarding survival and prognostic factors after radical surgery. Several prognostic factors for overall survival (OS) were assessed in patients treated surgically at five institutions from 2012 to 2018. Univariate and multivariate analyses were used to determine the independent risk factors of OS. A total of 142 patients were eligible for further analysis (mean age of 64.75 years, 56% males). Most patients presented with clear cell carcinoma (95%). The Mayo stage was predominantly 0-1 (88%). Distant visceral metastases at the time of diagnosis were present in 36 patients (25%), whereas nodal metastases were present in 24 patients (16.9%). During the follow-up period (mean of 32.5 months), the 3-year OS rate reached 68.2%. The majority of patients received no adjuvant treatment (

Indexed as

prognostic factorsradical nephrectomyrenal cell cancertumor thrombus

Identifiers

PMID34501296
PMCPMC8432091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.